New stomach drug may protect heart patients from dangerous bleeding

NCT ID NCT07479056

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if fexuprazan can prevent upper stomach bleeding in 400 heart patients at high risk for bleeding who must take two blood thinners after getting a heart stent. Participants receive either fexuprazan or the standard drug lansoprazole daily for 6 months. The goal is to see which drug better prevents bleeding, ulcers, and other stomach issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE (CAD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome cardiovascular disorder coronary artery disorder intermediate coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital

    RECRUITING

    Seoul, Eunpyeong-gu, 03312, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••